News
-
An analysis of data from Boehringer Ingelheim’s WISDOM study showed that withdrawal of ICS for COPD patients using the Spiriva Handihaler tiotropium bromide DPI plus salmeterol is associated with a higher exacerbation rate in patients… Read more . . .
-
In a leading article published in the Archives of Disease in Childhood, Andrew Bush and Louise Fleming of Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College London assert that “the diagnosis… Read more . . .
-
InCarda Therapeutics, which is developing an inhaled treatment for paroxysmal atrial fibrillation, has appointed former Gilead Senior VP for Cardiovascular Therapeutics Luiz Belardinelli as Chief Medical Officer, the company said. Belardinelli will continue as a… Read more . . .
-
Cohero Health and H&T Presspart have announced the availability of a new connected metered dose inhaler (eMDI). The eMDI collects actuation data from an integral sensor and transmits the data via Bluetooth to Cohero Health’s… Read more . . .
-
Chiesi has reported a greater than 9% increase in revenue from 2014 to 2015, with an almost 20% increase in sales of Foster (Fostair) beclamethasone/formoterol inhalers and an unspecified increase in sales of Clenil beclamethasone… Read more . . .
-
On March 10, 2016, the Philadelphia District Office of the FDA issued a warning letter to online retailer Dr Natural Healing about sales of epinephrine capsules packaged with a dry powder inhaler as a treatment… Read more . . .
-
Mundipharma has submitted a marketing application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the flutiform fluticasone/formoterol K-Haler breath-activated MDI for the treatment of asthma, the company said. The submission will be… Read more . . .
-
According to Boehringer Ingelheim Pharmaceuticals, the FDA has approved a supplemental NDA for the Stiolto Respimat tiotropium/olodaterol SMI for a labeling change to add quality of life data obtained from the OTEMTO 1&2 studies. Stiolto… Read more . . .
-
Kamada has submitted a Marketing Authorization Application for its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of AAT deficiency to the European Medicines Agency, and the filing EMA has validated the application, the company… Read more . . .
-
The upcoming RDD meeting to be held April 17-21, 2016 at the Westin Kierland Resort in Phoenix, AZ will offer several new features in addition to the usual scientific presentations, posters, exhibition, and networking opportunities. For the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.